ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Introduction of the second-generation TKIs, nilotinib and dasatinib as first-line treatment resulted in rapid and deep reduction of BCR/ABL1 allele transcripts, and this provided a possibility for long-term survival in CML [1,2].